---
title: "QuantHealth’s $45M Series B: Simulate the Trial Before You Enroll Patients"
description: "Qumra Capital led QuantHealth’s $45M Series B for AI clinical-trial simulation — predicting trial outcomes before first patient in, with Sanofi Ventures returning."
date: 2026-08-04T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "healthtech", "artificial-intelligence"]
source: https://venturecapitaltracker.com/2026-quanthealth-45m-series-b-clinical-trial-ai
---

# QuantHealth’s $45M Series B: Simulate the Trial Before You Enroll Patients

> Qumra Capital led QuantHealth’s $45M Series B for AI clinical-trial simulation — predicting trial outcomes before first patient in, with Sanofi Ventures returning.

**QuantHealth** raised a **$45 million Series B** in early **August 2026**, led by **Qumra Capital**, with **Sanofi Ventures**, Pitango HealthTech, Bertelsmann Healthcare Investments, and others participating. The Tel Aviv company sells a blunt idea: **run the trial in silico before you burn cash and patients**.

## Key facts

| Field | Detail |
| --- | --- |
| Company | QuantHealth (Tel Aviv) |
| Round | $45M Series B |
| Date | August 2026 (announced ~Aug 4) |
| Lead | Qumra Capital |
| Notable participants | Sanofi Ventures, Pitango HealthTech, BHI, Artofin, GC Ventures, others |
| Prior | $15M Series A (2023); Accenture strategic (2024) |
| Total raised | ~$70M+ (company / press) |
| Traction claim | 600+ simulated trials · ~30 indications · up to 90% predictive accuracy (company) |

## Who uses the product — and for what job

**Users:** clinical development, biometrics, and portfolio strategy teams inside biopharma.

**Job:** stress-test protocol design, endpoints, and population choices **before first patient in** — so effectiveness/safety failure modes show up in simulation, not Phase 3.

CEO Orr Inbar’s distinction (Fierce Healthcare): most AI in the space reacts mid-trial; QuantHealth claims to shape strategy **day one** via patient-level biology simulation (Katina workflow).

## Why now

- Clinical development is still where ~**90% of candidates die** — and where AI spend has lagged discovery hype.
- Sponsors face capital and time pressure; one avoided failed Phase 2/3 pays for many software seats.
- Strategic LPs (Sanofi Ventures) want tools that change **decision quality**, not slideware.

## Why these investors — portfolio fit

Qumra (Israeli growth) + Sanofi Ventures + Bertelsmann Healthcare is a **pharma-native syndicate**, not a generalist AI tourist round.

**Likely founder rationale:** raise from capital that already understands trial economics and can open sponsor introductions — Sanofi Ventures’ Cris De Luca called simulation “an important part of the drug development toolkit.”

| Investor | Fit |
| --- | --- |
| Qumra | Growth for Israeli healthtech category leaders |
| Sanofi Ventures | Strategic distribution + clinical credibility |
| Pitango / BHI | Healthcare specialist diligence |

We do not currently list Qumra or Sanofi Ventures as `/fund/` entities — treat names as press-sourced.

## Competitive map

| Player | Lane |
| --- | --- |
| Trial design consultancies | Human experts; slower, less repeatable |
| RWE / claims analytics | Post-market and observational; different job |
| Discovery AI (target/molecule) | Upstream of protocol design |
| CRO optimization tools | Execution efficiency after design is locked |

## Market signal

A **$45M B** with a strategic pharma venture arm returning says simulation-first trial design is graduating from pilot budgets into **platform spend**. Expansion plans (40+ indications; later commercial positioning) matter more than a single accuracy headline.

## When not to overclaim

- Do not equate “up to 90% accuracy” with regulatory acceptance — label it **company-reported**.
- Do not confuse QuantHealth with molecule discovery AI.
- Do not assume every indication transfers; oncology ≠ rare disease without validation.

## Practical takeaway

- **Founders (health AI):** Sell dollars of failed-trial risk avoided, with indication-level validation evidence.
- **Investors:** Prefer syndicates with pharma strategics when the buyer is clinical development.
- **Operators (sponsors):** Pilot on one asset class with pre-registered success metrics before enterprise rollout.

### Sources

1. Fierce Healthcare: https://www.fiercehealthcare.com/finance/quanthealth-raises-45m-series-b-accelerate-ai-driven-clinical-trial-simulations
2. FinSMEs (Aug 4, 2026): https://www.finsmes.com/2026/08/quanthealth-raises-45m-in-series-b-funding.html
3. Related: [/2026-august-9-investment-news-roundup-agents-voice-health](/2026-august-9-investment-news-roundup-agents-voice-health)